Chargement en cours...
Apalutamide in the treatment of castrate-resistant prostate cancer: evidence from clinical trials
Apalutamide (ARN-509) is a second-generation androgen receptor (AR) antagonist that was developed to inhibit AR-mediated prostate cancer cell proliferation. Following the initial promising clinical efficacy results in phase I and II clinical trials of patients with metastatic castrate-resistant pros...
Enregistré dans:
| Publié dans: | Ther Adv Urol |
|---|---|
| Auteurs principaux: | , |
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
SAGE Publications
2018
|
| Sujets: | |
| Accès en ligne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6295778/ https://ncbi.nlm.nih.gov/pubmed/30574205 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/1756287218811450 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|